Toca 511 (vocimagene amiretrorepvec), an amphotropic retroviral replicating vector (RRV), can successfully and safely deliver a functional, optimized cytosine deaminase (CD) gene to tumors in orthotopic glioma models. This agent, in conjunction with subsequent oral extended-release 5-fluorocytosine (5-FC) (Toca FC), is currently under investigation in patients with recurrent highgrade glioma. Temozolomide (TMZ) with radiation is the most frequently used first-line treatment for patients with glioblastoma, the most common and aggressive form of primary brain cancer in adults. However, subsets of patients with certain genetic alterations do not respond well to TMZ treatment and the overall median survival for patients who respond remains modest, suggesting that combinatorial approaches may be necessary to significantly improve outcomes. We show that in vitro TMZ delays but does not prevent RRV spread, nor interfere with Toca 511 þ 5-FC-mediated cell killing in glioma tumor cells, and in vivo there is no significant hematologic effect from the combination of 5-FC and the clinically relevant dose of TMZ. A synergistic long-term survival advantage is observed in mice bearing an orthotopic TMZ-sensitive glioma after Toca 511 administration followed by coadministration of TMZ and 5-FC. These results provide support for the investigation of this novel combination treatment strategy in patients with newly diagnosed malignant glioma. 
INTRODUCTION
We have previously shown that Toca 511 (vocimagene amiretrorepvec), a non-lytic, amphotropic retroviral replicating vector (RRV), 1 can successfully and safely deliver a functional, optimized cytosine deaminase (CD) gene to tumors in orthotopic glioma models. 2 The RRV-CD vector has specificity for replicating cells, and replication in non-malignant cells in vivo appears highly restricted. Toca 511, in conjunction with subsequent oral extended-release 5-fluorocytosine (5-FC) (Toca FC), is currently in clinical trials for recurrent high-grade glioma. Investigation of this new agent in patients with newly diagnosed HGG requires an understanding of the interaction of Toca 511 and Toca FC treatment with the current first-line standard of care for these tumors. Temozolomide (TMZ), an oral alkylating agent, is the standard chemotherapy treatment for patients with newly diagnosed glioblastoma multiforme (GBM), the most common and aggressive form of primary brain cancer in adults. 3, 4 An induction dose of TMZ at 75 mg m À 2 is used with concurrent radiation after resection for these patients followed by a maintenance dose of 150-200 mg m À 2 . However, tumors that express the enzymes O-6-methylguanine-DNA methyltransferase (MGMT) or O-6-alkylguanine-DNA alkyltransferase are relatively resistant to this treatment because of the enzymes' ability to repair the TMZ-induced methylation damage to the tumor DNA. Tumors with hypermethylated MGMT promoters have reduced gene expression and make less repair protein. [5] [6] [7] Nevertheless, both MGMT hypermethylated and unmethylated tumors almost inevitably recur and overall 5-year survival remains at o5%.
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The median overall survival for newly diagnosed GBM patients remains at o12 months, whereas the landmark Stupp study showed that for those receiving TMZ and radiation in addition to resection, it is approximately 14.6 months. 11, 12 When the MGMT promoter is methylated, the median survival is 21.7 months. 6, 11 It is clear that additional combinatorial approaches are necessary to significantly improve patient outcomes. Of particular interest are combinations of TMZ with agents that have complementary mechanisms of action, and strategies that minimize toxicity.
We have previously shown that Toca 511 selectively infects and replicates in the tumor environment. Toca 511 can then spread through the tumor when infected tumor cells produce infectious virus that buds off from the infected cell and spreads to neighboring replicating tumor cells. Infected cells and their daughter cells then constitutively express CD, rendering them capable of enzymatic conversion of the orally available prodrug 5-FC into the potent anticancer drug 5-fluorouracil (5-FU). Anabolites of 5-FU alter DNA and RNA synthesis, leading to cell cycle arrest and apoptosis. Through a process called metabolic cooperation, 5-FU can diffuse from infected cells and induce cell death in nearby replicating cells but spares nonreplicating tissue, which is resistant to 5-FU killing. This local Toca 511 þ 5-FC-mediated production of 5-FU avoids systemic exposure to high levels of 5-FU, especially given the very short half-life of 5-FU because of its rapid degradation by the ubiquitous catabolic enzyme dihydropyrimidine dehydrogenase. Currently, Toca 511-mediated gene transfer followed by cyclic courses of oral 5-FC (Toca FC) is under investigation in two Phase 1 ascending dose clinical trials in patients with recurrent high-grade glioma that has progressed after treatment with surgery, radiation and TMZ.
5-FU is a known radiosensitizing agent, and may also synergize with TMZ given its distinct mechanism of action. 13 We sought to investigate the compatibility of TMZ with Toca 511 and 5-FC in orthotopic mouse brain cancer models in anticipation of potential clinical use in the first-line setting. TMZ could potentially impact Toca 511 þ 5-FC treatment either positively or negatively. TMZ inhibition of replication could interfere with the initial infection and spread of the RRV. TMZ coadministered with 5-FC could impact the production of and effect of 5-FU-mediated tumor cell death. The combination of TMZ and 5-FC or 5-FU could result in unacceptable systemic toxicity. We examined the effect of TMZ in combination with Toca 511 and 5-FC in TMZ-sensitive and -resistant glioma cell lines both in vitro and in vivo in mice for efficacy and toxicity. We show that TMZ does not inhibit RRV spread nor interfere with Toca 511 þ 5-FC-mediated cell killing in the glioma tumor cells, regardless of their sensitivity to TMZ in vitro, and that there were no significant hematologic effects from 5-FC-TMZ combination treatments in vivo. We demonstrate that mice with a glioma from a TMZ-resistant glioma cell line survive equally well with and without TMZ administration when treated with Toca 511 and 5-FC as long as the TMZ is administered after Toca 511 and its initial time for spread. In addition, a synergistic long-term survival advantage is observed when TMZ in combination with Toca 511 þ 5-FC treatment was administered to mice bearing an orthotopic TMZ-sensitive glioma tumor. These preclinical results provide support for the investigation of this novel combination treatment strategy for newly diagnosed patients with primary GBM. Future studies will expand on this work by investigating Toca 511 þ 5-FC and TMZ with concomitant radiation.
MATERIALS AND METHODS

Drugs and reagents
TMZ (brand names: Temodar or Temodal) for in vitro assays was purchased from Sigma (St Louis, MO, USA); Temodar for in vivo studies were purchased from Merck (Whitehouse Station, NJ, USA). 5-FC for both in vitro and in vivo assays was purchased from Nantong Jinghua Pharmaceutical Company (Nantong, Jiangsu, China).
Toca 511
A detailed description of Toca 511 vector design and modification has been described previously. 1 Briefly, modifications were made to the plasmid pACE-green fluorescent protein (GFP) 14 to improve stability and increase convenience of transgene insertion to yield the vector pAC3-GFP. Genetic enhancements to the wild-type yeast CD gene were made as follows: (1) the codon usage was optimized for protein synthesis in human cells; and (2) three amino-acid changes were introduced (A23L, I140L and V108I) to increase thermal stability of the yeast CD protein. The plasmid pAC3-yCD2 was generated by substituting the modified CD gene into pAC3-GFP. Toca 511 is the vector produced from this plasmid using the production and formulation methods developed for clinical use.
Cell culture
Human glioma cell lines U-87MG (ATCC, Manassas, VA, USA; HTB-14), LN-18 (ATCC; CRL-2610), LN-229 (ATCC; CRL-2611), 8-MG-BA, 15 and the mouse glioma cell line Tu-2449 16 were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum, sodium pyruvate and glutamax (Hyclone, Rockford, IL, USA and Invitrogen, Grand Island, NY, USA). Cells were maintained in a humidified atmosphere with 5% CO 2 at 37 1C. When ready for in vivo implantation, cells were resuspended in Dulbecco's modified Eagle's medium media without any additives.
MGMT protein detection assay
Cells were lysed in ice-cold lysis buffer (0.5 mmol ethylenediaminetetraacetic acid, 150 mmol NaCl, 10 mmol Tris-HCl (pH 7.4), 0.5% NP-40, 0.5% sodium dodecyl sulfate, 0.1% sodium deoxycholate) supplemented with protease inhibitor cocktail (Sigma) for 15 min on ice followed by passing through a 27-G needle five times. Lysates were centrifuged at 13 000 r.p.m. for 20min at 4 1C. Protein concentrations of cell lysates were measured according to Bradford assay. Ten micrograms of protein was separated on sodium dodecyl sulfate-poly-acrylamide gel electrophoresis using NuPAGE 4-12% gradient gel (Invitrogen), and transferred onto the polyvinylidene fluoride membrane (GE Healthcare, Pittsburgh, PA, USA). Mouse monoclonal antibodies to human MGMT protein (Abcam, Cambridge, MA, USA) and to b-actin (Abcam) were used as primary antibody. Horse radish peroxidase-conjugated rabbit anti-mouse monoclonal antibody (Dako, Carpinteria, CA, USA) was used as the secondary antibody.
Clonogenic assay
Briefly, 500 cells were seeded in 6-cm tissue culture dishes. After an overnight incubation, cells were treated with different concentrations of TMZ (Sigma) in Dulbecco's modified Eagle's medium þ 10% fetal calf serum. Cells were cultivated for 10 days without replacing the medium, and thereafter washed with phosphate-buffered saline (PBS) and stained using May-Grü nwald staining solution (Sigma). Colonies containing more than 40 cells were manually counted. The results are reported as a percentage of the colonies in untreated cultures of each corresponding cell line. At least three independent experiments using each cell line were performed. The data are expressed as means ± s.e.m.
In vitro RRV-GFP spread
Two different TMZ schedules were tested. To test the effect of preincubation with TMZ, cells were seeded at a density of 1 Â In vitro 5-FC sensitivity assay Tu-2449 and U-87MG cells were infected with B1 Â 10 4 transducing units (TU) ml À 1 of Toca 511 in the presence of polybrene (8 mg ml À 1 ). Cells were passaged 2-3 times a week for 17 days. Fluorescence-activated cell sorting-based analysis of 4070A envelope (indicating Toca 511-infected cells) performed before sensitivity testing of these cells revealed that 89-99% of cells were infected. Cells were seeded on day 0 at a concentration of 1 Â 10 3 cells per well of a 96-well plate in 80 ml of culture medium (Dulbecco's modified Eagle's medium þ 10% fetal calf serum þ gentamicin (17 mg per 100 ml)). On day 1, 20 ml of culture medium containing 5-FC (range 0-1000 mg ml À 1 ), TMZ (range 0-100 mg ml À 1 ) or both drugs (5-FC (range 0-1.6 mg ml À 1 ) and TMZ (2 mg ml À 1 )) was added to the cells. Viability was measured on day 6 using Cell Proliferation Kit II (XTT) (Roche, Indianapolis, IN, USA) as recommended by the manufacturer.
Mice and intracranial surgeries
Female B6C3F1 or athymic nude-Foxn1^nu mice (age B8 weeks) were purchased from Harlan (Indianapolis, IN, USA or Udine, Italy). Mice were acclimated for 3-7 days after arrival. Mice underwent surgical placement of an indwelling guide cannula with a 3.0 mm projection implanted into the right striatum, and fitted with a cap containing a 3.5 mm projection for the Tu-2449 in vivo studies. Mice underwent surgical implantation of the tumor cells by Hamilton syringe for the U-87MG in vivo studies. The stereotaxic coordinates for both studies were AP ¼ 0.5 mm, ML ¼ 1.8 mm and DV ¼ 3.5 mm (from bregma).
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In vivo survival studies
The syngeneic cell line Tu-2449 was used as an orthotopic brain tumor model in B6C3F1 mice. Cell implantation and vector/vehicle injections were through an injection cannula with a 3.5 mm projection inserted through the guide cannula. B6C3F1 mice underwent intracranial implantation of 1.4 Â 10 4 tumor cells on day 0. On day 4, mice were injected with Toca 511 (3.15E4 TU g À 1 ) or vehicle control (IC; 5 ml per mouse) by intracranial infusion at 0.33 ml min (15 min, followed by a hold of 5 min). Starting on day 10, mice were treated with either PBS or 5-FC (500 mg kg À 1 per dose, i.p., b.i.d.) for 4 consecutive days, followed by 10 days without drug to allow vector spread. Cycles of 4-day on, 10-day off drug treatment were repeated three more times. In one set of studies, TMZ (25 mg kg À 1 per day, i.p., semel in die (SID) once a day) was administered on day 4 (the day of vector/vehicle injection) for 4 consecutive days, and then followed the 5-FC/PBS dosing schedule for four cycles. In the other set of studies, TMZ (25 mg kg À 1 per day, i.p.) SID was administered on the same days as the 5-FC/PBS treatments for four cycles.
The human malignant glioma cell line U-87MG was used as an orthotopic xenograft model in athymic nude mice. Cell implantation and vector/ vehicle injections were carried out using a Hamilton syringe on a stereotaxic frame. Athymic nude mice underwent intracranial implantation of 2 Â 10 5 tumor cells on day 0. On day 7, mice were injected with Toca 511 (3.4E4 TU g À 1 ) or vehicle control (IC; 5 ml per mouse for 10 min, followed by a hold of 5 min). Starting on day 14, mice were treated with either PBS or 5-FC (500 mg kg À 1 per day) IP SID for 4 consecutive days, followed by 10 days without drug to allow vector spread. Cycles of 4-day on, 10-day off 5-FC drug treatment were repeated three more times. TMZ (25 mg kg À 1 per day, intraperitoneally, SID) was administered on the same days as the 5-FC/PBS treatments for four cycles. All surviving mice were killed on day 180 after glioma cell injection.
Two different lots of Toca 511 were used for all in vivo studies. Toca 511 lot T511015-FNL had a starting titer of 1.7 Â 10 8 TU ml À 1 , whereas Toca 511 lot T511082-FNL had a starting titer of 6.3 Â 10 8 TU ml À 1 . Toca 511 doses are defined as TU g À 1 of brain, with the average mouse brain defined as 0.5 g.
In-life observations
Routine general health, in-life observations and body weights were collected throughout the course of the study. In-life observations were scored on a 0-4 point system for severity of each symptom. Mice with a cumulative score of 5 were euthanized. Mice with body weight loss of 420% for more than 2 days were euthanized. All animal protocols and experiments were approved by either the Institutional Animal Care and Use Committee (A4487-01) of Explora (San Diego, CA, USA) or the University of Veterinary Medicine Ethics Committee and Austrian government authorities (BMWF-68.205/0163-II/3b/2010; BMWF-68.205/0151-II/3b/ 2011).
Statistical analyses
Survival data were plotted using the Kaplan-Meier method, and were compared by the log-rank test or Student's t-test as noted. P-values of o0.05 were considered statistically significant in all analyses, which were carried out with Prism 5 statistical software (GraphPad Software, La Jolla, CA, USA). ) consistent with the lack of MGMT protein expression (Figure 1b) . LN-18, the human glioma cell line that expressed MGMT protein, was confirmed to be more resistant to TMZ up to a concentration of 100 mg ml . The mouse glioma cell line Tu-2449 was also resistant to TMZ up to a concentration of 100 mg ml À 1 (Figure 1b ).
RESULTS
Determination of TMZ sensitivity in glioma cells
Treatment with TMZ does not inhibit RRV-GFP spread in glioma cells in vitro
To test any possible effect of TMZ on the spread of Toca 511, the same panel of glioma cells was treated with different concentrations of TMZ depending on the TMZ sensitivity of the cells determined in the clonogenic assay in Figure 1b . In addition, vector with the same backbone as Toca 511 but encoding a GFP transgene (RRV-GFP) was used to assess vector spread by fluorescence-activated cell sorting analysis. Two TMZ treatment schedules were tested. The first schedule tested treatment with varying concentrations of TMZ before and during the time of vector infection, and the second schedule tested treatment with varying concentrations of TMZ at the same time as the addition of vector. In the first schedule, glioma cells were incubated with different concentrations of TMZ 24 h before the addition of RRV-GFP at a multiplicity of infection of 0.1. As shown in Figure 2a , all five glioma cells reached nearly 100% GFP positivity by day 12 without TMZ, indicating that the cells were susceptible to RRV-GFP infection. LN-229 and 8-MG-BA, two glioma cells that are most sensitive to TMZ in the panel (Figure 1b) , showed a delayed infectivity with 1 and 2 mg ml À 1 of TMZ compared with no TMZ control; however, the cells eventually reached 100% GPF positivity by day 16. There was an initial lag or decrease in GFP positivity at earlier time points (Figure 2a) . U-87MG cells also displayed a delayed infectivity with up to 5 mg ml À 1 of TMZ, whereas 10 mg ml À 1 of TMZ killed nearly 90% of the cells (Figures 2a  and 1b) . Two relatively TMZ-resistant glioma cell lines, LN-18 and Tu-2449, at TMZ concentration up to 20 mg ml
, also showed a pattern of delayed infectivity, but reached nearly 100% of GFP positivity by day 19 (Figure 2a ). TMZ at 50 mg ml À 1 or higher reduced infectivity in Tu-2449 cell line. In the second schedule, ), and the two Toca 511-transduced cells were sensitive to 5-FC in a dose-dependent manner (Figure 3a) . In addition, cell viability was examined in the nontransduced and transduced cell lines treated with increasing amounts of TMZ. Consistent with results from Figure 1b , U-87MG cells were sensitive to TMZ and Tu-2249 cells were relatively resistant to TMZ (Figure 3b) . The Toca 511-transduced cells also followed the same trend as the naive cells in TMZ sensitivity; in addition, the expression of the transgene CD protein from Toca 511-transduced glioma cells did not affect the cells' sensitivity to TMZ (Figure 3b ). When these cells were treated with a combination of TMZ (2 mg ml À 1 ) and 5-FC (titrating amounts) concomitantly, the data showed that TMZ did not inhibit 5-FC killing in Toca 511-transduced cells, regardless of their TMZ sensitivity (Figure 3c ). Table 1) .
To test the effect of the combination therapy of TMZ and Toca 511 þ 5-FC treatment in a TMZ-resistant cell line in vivo, the Tu-2449 mouse glioma cell line was chosen as this line has been used as an orthotopic, syngeneic mouse glioma model in B6C3/F1 hybrid mice. 16, 22 Previous studies have shown that this model displays several of the features of human glioblastoma, and is highly angiogenic. 18 Tu-2449 glioma cells were implanted intracranially into syngeneic B6C3/F1 mice (n ¼ 18 per treatment group), and Toca 511 (3.15E4 TU g À 1 ) or vehicle control was administered once intratumorally 4 days after tumor implant. Mice were also given TMZ treatment (25 mg kg À 1 per day, intraperitoneally, SID) starting on the same day as the vector injection for 4 consecutive days (days 4-7). Mice were treated again with TMZ (25 mg kg À 1 per day, intraperitoneally, SID), and 5-FC (500 mg kg À 1 per day, intraperitoneally, twice a day) or PBS on days 10-13. Both drugs were administered for 4 consecutive days, followed by 10 days without drug to allow more vector spread. Cycles of the TMZ ± 5-FC treatment were repeated three times (starting on days 24, 38 and 52). All surviving mice were killed on day 90 after glioma cell implantation (Figure 4a) .
No treatment-related effects on body weight were observed during the study. There were no treatment-related differences in incidence of in-life observations across groups through day 90. Mice with large tumor burden, regardless of treatment group, showed weight loss and increased hunching and lethargy. Treatment of Toca 511 þ 5-FC (intraperitoneally, twice a day) with or without TMZ resulted in statistically prolonged survival compared with the control group (Toca 511±PBS), with a median survival of 22.5 days (P-values ¼ 0.0001 and 0.0088, respectively). Treatment of mice with Toca 511 þ 5-FC (intraperitoneally, twice a day) with TMZ resulted in statistically prolonged survival compared with the TMZ control group (buffer±TMZ±5-FC, intraperitoneally, twice a day), with a median survival of 71 and 22 days, respectively (P-value ¼ 0.004). However, mice treated with Toca 511 þ 5-FC (intraperitoneally, twice a day) and TMZ during Toca 511 treatment and spread (days 4-7) had a decreased survival rate compared with mice treated with Toca 511 þ 5-FC (intraperitoneally, twice a day) (P-value ¼ 0.0176) (Figure 4a ). The median survival in this group was not determined as 450% of the animals survived to the end of the experiment. These results indicate TMZ in combination with Toca 511 þ 5-FC treatment had a negative impact on the therapeutic effect of Toca 511 þ 5-FC (intraperitoneally, twice a day) treatment when TMZ was administered during the initial vector infection and spread period.
Combination of TMZ and 5-FC treatment shows equivalent efficacy to 5-FC alone in a TMZ-resistant orthotopic glioma model, when administered after Toca 511 infection and spread A different TMZ dosing schedule was implemented in a new study to further investigate the effect of TMZ in Toca 511 þ 5-FC treatment in the Tu-2449 TMZ-resistant glioma line. Tu-2449 mouse glioma cells were implanted intracranially into the syngeneic B6C3F1 mice (n ¼ 33 per treatment group), and Toca 511 (3.15E4 TU g À 1 ) or vehicle control was administered intratumorally 4 days after tumor implant. However, TMZ was not administered during the initial vector infection and spread period (days 4-7) unlike the previous study. Five days after vector injection, mice were treated with TMZ (25 mg kg À 1 per day, intraperitoneally, twice a day), 5-FC (500 mg kg À 1 per day, intraperitoneally, twice a day) or PBS. Drugs were administered over 4 consecutive days followed by 10 days without drug to allow more vector spread. Cycles of the drug treatment were repeated three more times (starting on days 24, 38 and 52). All surviving mice were killed on day 70 after glioma cell implantation (Figure 4b) .
As in the previous study, no treatment-related effects on body weight or clinical observations were observed during the study. Mice with large tumor burden, regardless of treatment group, showed weight loss and increased hunching and lethargy. Treatment of Toca 511 þ 5-FC (intraperitoneally, twice a day) with or without TMZ resulted in statistically prolonged survival compared with the control group (Toca 511 ± PBS) (P-values ¼ 0.05 and 0.02, respectively). Treatment of mice with Toca 511 þ 5-FC (intraperitoneally, twice a day) with TMZ resulted in statistically prolonged survival compared with the TMZ control group (buffer±TMZ±5-FC, intraperitoneally, twice a day), with a median survival of 56 and 31 days, respectively (P value ¼ 0.004). Furthermore, mice treated with Toca 511 þ 5-FC (intraperitoneally, twice a day) with TMZ resulted in similar survival compared with mice treated with Toca 511 þ 5-FC (intraperitoneally, twice a day) with an undefined median survival exceeding 70 days , which is the dose used during first-line radiation therapy) led to mild changes in hematological parameters (Supplementary Table 2 ).
U-87MG cells were implanted intracranially into athymic mice, and Toca 511 (3.4E4 TU g) or NaCl were injected intratumorally 7 days after tumor implantation. Treatment with TMZ (25 mg kg À 1 per day, intraperitoneally, SID), 5-FC (500 mg kg À 1 per day, intraperitoneally, SID) or PBS was initiated on day 14 to allow 6 days for initial vector infection and spread. Both drugs were administered for 4 consecutive days, followed by 10 days without drug to allow more vector spread. Cycles of the treatment were repeated three times (starting on days 28, 42 and 56). All surviving mice were killed on day 180 after glioma cell implantation.
Mice treated with Toca 511 þ 5-FC showed an increase in median survival (85 days) compared with the Toca 511 ± PBS control mice (32 days) (P-value o0.0001) ( Figure 5 ). Mice treated with Toca 511 þ 5-FC in combination with lower dose TMZ showed a significant increase in survival compared with the no vector, 5-FC ± lower dose TMZ control mice, with a median survival of undefined and 40.5 days, respectively (P-value ¼ 0.001) ( Figure 5 ). In addition, mice treated with Toca 511 þ 5-FC in combination with lower dose TMZ resulted in significantly prolonged survival compared with the Toca 511 þ 5-FC group (P-value ¼ 0.001). These results demonstrate a synergistic efficacy when combining lower dose TMZ with Toca 511 þ 5-FC treatment in a TMZ-sensitive glioma mouse model. Efficacy in glioma models for TMZ and Toca 511 þ 5-FC treatment T Huang et al with radiation for the treatment of malignant glioma did not significantly improve survival. [23] [24] [25] [26] However, recent studies suggest that minimal response may have resulted from the limited availability of 5-FU in the tumor and not from the intrinsic resistance of gliomas to fluoropyrimidines. 27, 28 Pharmacokinetic studies show that 5-FU crosses the blood-brain barrier, 29, 30 but therapeutic concentrations may not be achieved in brain tissues at acceptable levels of systemic toxicity. Toca 511 þ 5-FC is designed to overcome this limitation by directly producing 5-FU within the tumor, sparing normal tissue from extensive exposure. 5-FU is known to synergize with radiation, 13 and may also synergize with TMZ. DNA damage induced by anabolites of 5-FU through incorporation of 5-FdUTP into DNA and reduction of thymidine pools by inhibition of thymidylate synthase via 5-FdUMP may reduce the repair activity of MGMT, thereby potentiating the effects of TMZ on DNA replication. 31, 32 Capecitabine (5-DFUR), an oral prodrug for 5-FU, and TMZ were synergistic for the induction of apoptosis in human NET cell lines. 33 The combination is also under investigation for the treatment of breast cancer metastatic to the brain. 34 TMZ is currently a standard first-line chemotherapy for glioma, and patients with tumors containing a methlylated MGMT promoter are generally more responsive to TMZ therapy. In this study, we investigated the effect of combining TMZ and RRV-GFP and/or Toca 511 in TMZ-sensitive and -resistant cells both in vitro and in vivo. Our results demonstrate that TMZ treatment, administered either before or concomitantly, with RRV-GFP in the glioma cell lines examined did not inhibit vector spread until concentrations that also resulted in significant cell death (see Figure 1) were reached. The observation of initial lag in vector infection/spread was most likely due to cell killing or decreased cell proliferation caused by TMZ. Treatment with TMZ and Toca 511 þ 5-FC in vitro also demonstrated that there was no inhibitory effect on cell killing compared with Toca 511 þ 5-FC treatment alone. It is important to note again that infection and spread of RRV requires cell division. Thus, affecting cellular proliferation would also influence RRV infection and spread, as observed in our in vitro experiments with higher than tolerated TMZ concentrations for the tumor cells.
DISCUSSION
TMZ and 5-FU both exploit mismatch repair mechanisms to induce tumor cell death; however, resistance to one does not necessarily confer resistance to the other. TMZ (10 mol l À 1 ) was shown to have activity in 5 of 11 tumor cell lines of various types resistant to fluorouracil. 35 Our results also indicate that TMZ-sensitive and -resistant cells are both susceptible to RRV infection and sensitive to subsequent 5-FU-induced cell death.
In a TMZ-resistant glioma mouse model (Figure 4a ), mice that were given TMZ concomitantly with Toca 511 had reduced survival compared with mice treated with Toca 511 þ 5-FC alone. This result may be due to TMZ treatment owing to a decrease in tumor growth, which in turn affected the initial infection and spread of Toca 511 in tumor cells. This is consistent with our in vitro data that treatment of TMZ caused a lag in RRV-GFP spread (Figure 3) . Although the surviving cells eventually reached 100% GFP positivity by day 16 or 19 in the in vitro assays, the delay in RRV infection and spread due to TMZ administration in vivo may be the mechanism that decreases survival in our mouse efficacy models. However, mice that were given TMZ concomitantly only during 5-FC treatment, and not during the initial vector spread, had a comparable survival to mice treated with Toca 511 þ 5-FC (Figure 4b ), further suggesting that TMZ mediated slowing of initial infection reduces efficacy and survival. We note here that suboptimal Toca 511 dosing 2 was intentionally used in these experiments to allow detection of either beneficial or detrimental effects of TMZ cotreatment.
Mice treated with TMZ in combination with Toca 511 þ 5-FC in a TMZ-sensitive glioma model had an increased survival rate compared with Toca 511 þ 5-FC alone ( Figure 5 ). Use of an immunocompromised animal model for Toca 511 ± suboptimal 5-FC treatment in orthotopic glioma models often results in prolonged survival but the mice eventually succumb to tumor burden, 17 whereas in the immunocompetent mouse Tu2449 glioma model, tumors usually do not recur after four rounds of 5-FC treatment. 2 This indicates the importance of immune components in conjunction with Toca 511 þ 5-FC treatment for complete elimination of tumor (manuscript in preparation). In this study, the triple combination of TMZ and Toca 511 þ 5-FC resulted in prolonged survival even in the absence of an active immune response. As far as we are aware, this is the first demonstration of therapeutic synergy for the combination of TMZ and any CD/5-FC prodrug-activating system. 5-FU and TMZ may potentiate the synergistic tumor cell killing by causing DNA damage via two different complementary mechanisms. Efficacy in glioma models for TMZ and Toca 511 þ 5-FC treatment T Huang et al TMZ is used clinically in conjunction with tumor irradiation, and the interaction of Toca 511 plus 5-FC with radiation in animal models is being separately investigated. However, as TMZ is a systemic orally available drug, we considered the interaction of Toca 511 and 5-FC with TMZ as a clinically relevant situation where a negative interaction could possibly be observed. A potentially useful therapeutic strategy suggested by the experiments in this investigation is to treat newly diagnosed GBM patients after their initial resection, but before the initiation of TMZ (and radiation), with Toca 511 and allow time for spread before initiating 5-FC, TMZ and radiation treatments. Such a timetable seems likely to be compatible with the clinical standard of care for newly diagnosed GBM patients.
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